Project Grant R01AI201499
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $728,222 on April 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate interferon signaling in lupus nephritis. The award funds research examining how type I, II, and III interferon responses in kidney tissue parenchyma protect against lupus nephritis, a severe manifestation of systemic lupus erythematosus associated with significant morbidity and mortality....
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded The Johns Hopkins University $232,695 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify mitochondrial antigens in systemic lupus erythematosus. The research elucidates antigenic targets of anti-whole mitochondria autoantibodies (AWHM) in SLE patients and their contribution to...
- The National Institute of Allergy and Infectious Diseases awarded La Jolla Institute for Immunology $929,095 on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize immune cell populations in lymphoid tissue from systemic lupus erythematosus patients and healthy controls using minimally invasive nasal swab sampling combined with flow cytometry and transcriptomic profiling. The research addresses gaps in understanding tissue-specific immune...
- The National Institute of Allergy and Infectious Diseases awarded $499,175 to the University of Pittsburgh on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct genetic and functional dissection of tissue-infiltrating and age-associated B cells in murine lupus models. The research aims to identify and characterize pathogenic B cell subsets in systemic lupus erythematosus (SLE), with particular focus on age-associated B cells (ABCs) that...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $647,571 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate regulatory T cell dysfunction as a biomarker for personalized therapeutic targeting in systemic lupus erythematosus. The research uses single-cell transcriptomics to characterize two transcriptionally distinct patient subgroups based on naive regulatory T cell (nTreg)...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $462,052 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study ETS2-mediated monocyte activation in systemic lupus erythematosus. The research investigates the role of erythroblast transformation specific 2 (ETS2), a transcription factor, in regulating inflammatory responses in human monocytes and macrophages exposed to lupus immune complexes. The project builds...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $855,342 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the pathogenic roles of follicular helper T (TFH) cells in systemic lupus erythematosus. The research seeks to understand how SLE disease settings reprogram TFH cell differentiation and function to promote autoimmune disease pathology. The recipient will assess how the IGF1R/IGFBP4...
- The National Institute of Allergy and Infectious Diseases awarded The Feinstein Institutes for Medical Research $209,375 on April 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of autophagy in B cell tolerance and its relationship to systemic lupus erythematosus. The research examines how autophagy defects contribute to loss of B cell tolerance in autoimmune disease, specifically exploring crosstalk between autophagy pathways and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Massachusetts Medical School $251,250 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the role of macrophage-associated receptor with collagenous structure (MARCO) as an innate immune checkpoint in systemic lupus erythematosus (SLE). The project will develop and validate novel experimental models to understand the interferon-MARCO signaling axis and how...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded The Leland Stanford Junior University $127,926 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize autoreactive B cells and their roles in systemic lupus erythematosus (SLE) pathogenesis using immune organoids. The research investigates how autoreactive B cells transition from a...
The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $748,333 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to examine interferon-dependent and interferon-independent pathways in systemic lupus erythematosus. The research will classify SLE patients into mechanistically distinct disease subsets based on interferon expression patterns and identify factors that produce an interferon signature independent of actual interferon elevation. The project uses patient cohorts with cutaneous lupus and SLE alongside state-of-the-art technologies to characterize clinical endotypes linked to Type I interferon and to determine the identity of interferon-independent mechanisms that mirror interferon-induced gene expression in a subset of SLE patients. The work addresses why only some SLE patients expressing the interferon signature benefit from clinical trials targeting the Type I interferon pathway and why inhibiting Type II interferon has failed to treat SLE. Place of performance is Baltimore, Maryland. The period of performance runs from August 14, 2026, through July 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $748.3k | 8/14/26 |